Predictive model accuracy in estimating last Δ9-tetrahydrocannabinol (THC) intake from plasma and whole blood cannabinoid concentrations in chronic, daily cannabis smokers administered subchronic oral THC

Drug and Alcohol Dependence

Volumn 125, Issue 3, 2012, Pages 313-319

  Karschner, Erin L ^a   Schwope, David M ^a   Schwilke, Eugene W ^a   Goodwin, Robert S ^a   Kelly, Deanna L ^b   Gorelick, David A ^a   Huestis, Marilyn A ^a  

^a NATIONAL INSTITUTE ON DRUG ABUSE   (United States)

^b UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

Author keywords

9 tetrahydrocannabinol; Cannabinoids; Cannabis; Chronic; Marijuana; Predictive models

Indexed keywords

DRONABINOL;

ADULT; ARTICLE; CANNABIS ADDICTION; CANNABIS SMOKING; CHRONIC DRUG ADMINISTRATION; CLINICAL ARTICLE; DIAGNOSTIC ACCURACY; DISEASE SEVERITY; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG DISTRIBUTION; DRUG EXPOSURE; DRUG SCREENING; HUMAN; MALE; MULTIPLE DRUG DOSE; PREDICTIVE VALIDITY; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; SMOKING CESSATION;

ADMINISTRATION, ORAL; ADOLESCENT; ADULT; ALGORITHMS; BODY BURDEN; BODY MASS INDEX; CANNABINOIDS; FORECASTING; GAS CHROMATOGRAPHY-MASS SPECTROMETRY; HALLUCINOGENS; HUMANS; MALE; MARIJUANA SMOKING; MODELS, STATISTICAL; SOLID PHASE EXTRACTION; TETRAHYDROCANNABINOL; YOUNG ADULT;

CANNABIS; CANNABIS SATIVA;

EID: 84866400968     PISSN: 03768716     EISSN: 18790046     Source Type: Journal    
DOI: 10.1016/j.drugalcdep.2012.03.005     Document Type: Article

References (19)

1. André C.J.-F.J., Bento R.M., Damasceno L.M., Aquino-Neto F.R. Delirium following ingestion of marijuana present in chocolate cookies. CNS Spectr. 2006, 11:262-264.
2. Chaudry H.R.M.H., Bashir A., Suliman T. Cannabis psychosis following bhang ingestion. Br. J. Addict. 1991, 86:1075-1081.
3. Gorelick D.A., Goodwin R.S., Schwilke E., Schwope D.M., Darwin W.D., Kelly D.L., McMahon R.P., Liu F., Ortemann-Renon C., Bonnet D., Huestis M.A. Antagonist-elicited cannabis withdrawal in humans. J. Clin. Psychopharmacol. 2011, 31:603-612.
4. Gorter R.W.B.M., Cobian E.P., van der Sluis W. Medical use of cannabis in the Netherlands. Neurology 2005, 64:917-919.
5. Hagenbach U., Luz S., Ghafoor N., Berger J.M., Grotenhermen F., Brenneisen R., Mader M. The treatment of spasticity with [Delta]9-tetrahydrocannabinol in persons with spinal cord injury. Spinal Cord 2006, 45:551-562.
6. Haney M., Ward A.S., Comer S.D., Foltin R.W., Fischman M.W. Abstinence symptoms following oral THC administration to humans. Psychopharmacologia 1999, 141:385-394.
7. Huestis M.A., Henningfield J.E., Cone E.J. Blood cannabinoids. II. Models for the prediction of time of marijuana exposure from plasma concentrations of delta-9-tetrahydrocannabinol (THC) and 11-nor-9-carboxy-delta-9-tetrahydrocannabinol (THCCOOH). J. Anal. Toxicol. 1992, 16:283-290.
8. Huestis M.A., Barnes A., Smith M.L. Estimating the time of last cannabis use from plasma delta9-tetrahydrocannabinol and 11-nor-9-carboxy-delta9-tetrahydrocannabinol concentrations. Clin. Chem. 2005, 51:2289-2295.
9. Huestis M.A., Elsohly M., Nebro W., Barnes A., Gustafson R.A., Smith M.L. Estimating time of last oral ingestion of cannabis from plasma THC and THCCOOH concentrations. Ther. Drug Monit. 2006, 28:540-544.
10. Jones R.T., Benowitz N. The 30-day trip - clinical studies of cannabis tolerance and dependence. The Pharmacology of Marijuana 1976, 627-643. Raven Press, New York. M. Braude, S. Szara (Eds.).
11. Karschner E., Schwilke E., Lowe R., Darwin W., Pope H., Herning R., Cadet J., Huestis M. Do Delta 9-Tetrahydrocannabinol concentrations indicate recent use in chronic cannabis users?. Addiction 2009, 104:2041-2048.
12. Karschner E., Schwilke E., Lowe R., Darwin W.D., Herning R., Cadet J., Huestis M. Implications of plasma Delta9-tetrahydrocannabinol, 11-hydroxy-THC, and 11-nor-9-carboxy-THC concentrations in chronic cannabis smokers. J. Anal. Toxicol. 2009, 33:469-477.
13. Lowe R.H., Karschner E.L., Schwilke E.W., Barnes A.J., Huestis M.A. Simultaneous quantification of delta-9-tetrahydrocannabinol (THC), 11-hydroxy-delta-9-tetrahydrocannabinol (11-OH-THC), and 11-nor-delta-9-tetrahydrocannabinol-9-carboxylic acid (THCCOOH) in human plasma using two-dimensional gas chromatography, cryofocusing, and electron impact-mass spectrometry. J. Chromatogr. A 2007, 1163:318-327.
14. Lynch M.E., Young J., Clark A.J. A case series of patients using medicinal marihuana for management of chronic pain under the Canadian marijuana medical access regulations. J. Pain Symptom Manage. 2006, 32:497-501.
15. Schwilke E.W., Karschner E.L., Lowe R.H., Gordon A.M., Cadet J.L., Herning R., Huestis M.A. Intra- and inter-subject whole blood/plasma cannabinoid ratios determined by 2-dimensional, electron impact-gas chromatography, mass spectrometry with cryofocusing. Clin. Chem. 2009, 55:1188-1195.
16. Schwilke E.W., Schwope D.M., Karschner E.L., Lowe R.H., Darwin W.D., Kelly D.L., Goodwin R.S., Gorelick D.A., Huestis M.A. Delta9-tetrahydrocannabinol (THC), 11-hydroxy-THC, and 11-nor-9-carboxy-THC plasma pharmacokinetics during and after continuous high-dose oral THC. Clin. Chem. 2009, 55:2180-2189.
17. Skopp G., Potsch L. Cannabinoid concentrations in spot serum samples 24-48h after discontinuation of cannabis smoking. J. Anal. Toxicol. 2008, 32:160-164.
18. Smith P. New approaches in the management of spasticity in multiple sclerosis patients: role of cannabinoids. Ther. Clin. Risk Manag. 2010, 6:59-63.
19. Toennes S.W., Ramaekers J.G., Theunissen E.L., Moeller M.R., Kauert G.F. Comparison of cannabinoid pharmacokinetic properties in occasional and heavy users smoking a marijuana or placebo joint. J. Anal. Toxicol. 2008, 32:470-477.